The number of unwanted pregnancies is increasing, becoming one of the world's major concerns. For instance, according to the World Health Organization (WHO), unintended pregnancies are a major public health concern. According to the International Federation of Medical Students' Associations' 2018 report, approximately 22 million unsafe abortions are performed globally each year, resulting in the deaths of an estimated 47,000 women. However, in recent years, increased contraception awareness has contributed to both a decrease in unplanned pregnancies and the growth of the intra-uterine contraceptive devices market.
According to Data Bridge Market Research the Intra-Uterine Contraceptive Devices Market accounted for USD 4.09 billion in 2021, and expected to reach USD 6.00 billion by 2029. The market is expected to grow with a CAGR of 4.70% in the forecast period of 2022 to 2029.
“Increasing R&D Activities to Facilitate Market Growth”
Increasing R&D activities in the development of novel devices is also contributing to market growth. For instance, Cairo University, is conducting a clinical trial to evaluate the safety and efficacy of an intrauterine copper device in patients undergoing cesarean delivery. The trial began in December 2020 and is scheduled to end in April 2022. Furthermore, the lower cost of these devices has made IUDs one of the most commonly used contraceptive devices in the United States.
What restraints the growth of Intra-Uterine Contraceptive Devices Market?
“Risks associated with Intra-Uterine Contraceptive Devices”
According to a study published in the Society of Obstetricians and Gynecologists of Canada (SOGC) 2020 by Amanda Black, Canadian women and couples who want to avoid pregnancy during the COVID-19 pandemic 2020 are more likely to develop an unmet need for family planning due to a lack of access to contraceptive care or methods. Furthermore, social isolation may increase unintended pregnancy by exposing women to unprotected sexual encounters, reproductive coercion and intimate personal violence.
Segmentation: Intra-Uterine Contraceptive Devices Market
The intra-uterine contraceptive devices market is segmented on the basis of type, product type and end user.
- On the basis of type, the intra-uterine contraceptive devices market is segmented into hormonal intrauterine device and copper intrauterine device.
- On the basis of product type, the intra-uterine contraceptive devices market can be segmented into mirena, skyla, paragard, essure, levosert and others.
- The end user segment of intra-uterine contraceptive devices market is segmented into hospitals, gynecology clinics, community health care centers and others.
Regional Insights: North America is expected to dominate the Intra-Uterine Contraceptive Devices Market
North America is expected to dominate the market due to the region's technological advancements in intrauterine contraceptive devices. IUDs are one of the most effective forms of reversible contraception, and both women and healthcare providers are becoming more interested in this method. The United States market has shown the highest demand for both hormone-free copper and hormone-based IUDs.
- In addition, the Asia-Pacific region is likely to register the highest growth rate during the forecast period of 2022 to 2029 due to the growing awareness among the women for contraceptive devices and their benefits.
To know more about the study visit, https://www.databridgemarketresearch.com/ar/reports/global-intra-uterine-contraceptive-devices-market
Recent Developments in Intra-Uterine Contraceptive Devices Market
- In 2021, Sebela Pharmaceuticals Inc. collaborated with PRA Health Sciences to conduct a phase III clinical trial to evaluate LevoCept. The product is a reversible long-acting intrauterine system for contraception safety, tolerability, and efficacy. The trial will be completed in June 2027.
- In 2020, Agile Therapeutics, Inc. received FDA approval for Twirla (levonorgestrel and ethinyl estradiol) transdermal system, which is specified as a method of contraception for use in women of reproductive potential with a BMI of 30 kg/m2 who require a combined hormonal contraceptive.
The Prominent Key Players Operating in the Intra-Uterine Contraceptive Devices Market Include:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bayer AG (Germany)
- EUROGINE S.L (Spain)
- CooperSurgical Inc. (U.S.)
- Pfizer Inc. (U.S.)
- HLL Lifecare Limited (India)
- OCON Medical Ltd. (Israel)
- Prosan International BV (Netherlands)
- Melbea Innovations (Hungary)
- AbbVie Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- DKT International (U.S.)
- Medisafe Distribution Inc. (Canada)
- Medicines360 (U.S.)
- Pregna International Limited (India)
- Egemen International (Turkey)
Above are the key players covered in the report, to know about more and exhaustive list of intra-uterine contraceptive devices market companies contact, https://www.databridgemarketresearch.com/ar/contact
Research Methodology: Global Hip Intra-Uterine Contraceptive Devices Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
